{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:46:06Z","timestamp":1785433566482,"version":"3.56.0"},"reference-count":33,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ASHE"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S2732494X25102842_as1\">\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate antibiotic utilization in relation to antimicrobial stewardship activities in a 170-bed Touro Infirmary hospital in New Orleans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S2732494X25102842_as2\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We evaluated antibiotic utilization for antipseudomonal beta-lactams, methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      antibiotics (anti-MRSA), fluoroquinolones, and ceftriaxone in relation to antimicrobial stewardship activities that were implemented at the hospital and monitored between August 1, 2018, and August 31, 2025. We recorded days of antibiotic therapy and days of intravenous antibiotic administration for 19-months baseline, during 10 months of COVID-19-dictated antibiotic utilization, and during 14 months of MRSA PCR testing at Touro (Antimicrobial Stewardship Intervention [ASI] 1), 20 months of blood culture identification (BCID) at Touro (ASI 2, time 1), followed by 22 months of BCID and other cultures sent out to University Medical Center (ASI 2, time 2).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S2732494X25102842_as3\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      During the observation period, days of therapy for antipseudomonal beta-lactams, anti-MRSA, and fluoroquinolones consistently and significantly decreased from baseline to ASI 2, time 2 (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .0001 for each decrease). Days of therapy for ceftriaxone significantly increased from ASI 1 to ASI 2, time 2 (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .0001). Days of therapy for all antibiotics consistently decreased from baseline to ASI 2, time 1 (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .0001) but not through time 2 (\n                      <jats:italic>P<\/jats:italic>\n                      = .571). Days of intravenous administration of antibiotics significantly decreased from baseline to the COVID-19 period (\n                      <jats:italic>P<\/jats:italic>\n                      = .002) and decreased again significantly from ASI 1 to ASI 2, time 1 (\n                      <jats:italic>P<\/jats:italic>\n                      = .003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S2732494X25102842_as4\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Clinical microbiology laboratories integrated into Antimicrobial Stewardship Program are associated with reductions in days of antibiotic therapy and days of intravenous antibiotic administration at Touro Infirmary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/ash.2025.10284","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:00:48Z","timestamp":1775034048000},"source":"Crossref","is-referenced-by-count":0,"title":["Antimicrobial Stewardship Program in an acute care hospital in New Orleans: impact on antibiotic utilization"],"prefix":"10.1017","volume":"6","author":[{"given":"Michelle D.","family":"Blyth","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qv8fp92","id-type":"ROR","asserted-by":"publisher"}],"name":"Louisiana State University Health Sciences Center"},{"name":"Touro Infirmary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4863-8087","authenticated-orcid":false,"given":"Bionca W.","family":"Conway","sequence":"additional","affiliation":[{"name":"Touro Infirmary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonzie","family":"Beamon","sequence":"additional","affiliation":[{"name":"Touro Infirmary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4767-5309","authenticated-orcid":false,"given":"M. Jacques","family":"Nsuami","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qv8fp92","id-type":"ROR","asserted-by":"publisher"}],"name":"Louisiana State University Health Sciences Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8716-7465","authenticated-orcid":false,"given":"Julio E.","family":"Figueroa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qv8fp92","id-type":"ROR","asserted-by":"publisher"}],"name":"Louisiana State University Health Sciences Center"},{"name":"Touro Infirmary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"S2732494X25102842_ref9","first-page":"25","volume-title":"Methicillin-Resistant Staphylococcus aureus (MRSA) Protocols, Methods in Molecular Biology","volume":"1085","author":"Sowash","year":"2014"},{"key":"S2732494X25102842_ref26","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2747"},{"key":"S2732494X25102842_ref12","unstructured":"12. CDC. Core elements of hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC. 2019. https:\/\/www.cdc.gov\/antibiotic-use\/core-elements\/hospital.html. Accessed July 18, 2025."},{"key":"S2732494X25102842_ref7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/bs.ircmb.2023.03.009","article-title":"Side effects of antibiotics and perturbations on mitochondria functions","volume":"377","author":"Morroni","year":"2023","journal-title":"Int Rev Cell Mol Biol"},{"key":"S2732494X25102842_ref13","doi-asserted-by":"publisher","DOI":"10.4081\/idr.2017.6839"},{"key":"S2732494X25102842_ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/55.6.1196S"},{"key":"S2732494X25102842_ref27","unstructured":"27. BioM\u00e9rieux. BIOFIRE\u00ae blood culture identification 2 (BCID2) panel. EN REF: RFIT-ASY-0147 RFIT-PRT-0841-05. BIOFIRE\u00ae BCID 2 Panel Package Insert. 2023: 121."},{"key":"S2732494X25102842_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.05.005"},{"key":"S2732494X25102842_ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.1938"},{"key":"S2732494X25102842_ref29","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/152752"},{"key":"S2732494X25102842_ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.1.61"},{"key":"S2732494X25102842_ref19","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012-0651-OA"},{"key":"S2732494X25102842_ref14","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000565"},{"key":"S2732494X25102842_ref17","doi-asserted-by":"publisher","DOI":"10.1086\/656248"},{"key":"S2732494X25102842_ref8","doi-asserted-by":"publisher","DOI":"10.1186\/2047-2994-2-31"},{"key":"S2732494X25102842_ref25","first-page":"S25","article-title":"The role of the clinical microbiology laboratory in the diagnosis of selected infectious processes","volume":"49","author":"Baron","year":"2021","journal-title":"J Clin Microbiol"},{"key":"S2732494X25102842_ref30","first-page":"259","volume-title":"Methicillin-Resistant Staphylococcus aureus (MRSA) Protocols, Methods in Molecular Biology","volume":"1085","author":"Anstead","year":"2014"},{"key":"S2732494X25102842_ref31","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/8.3.165"},{"key":"S2732494X25102842_ref33","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol"},{"key":"S2732494X25102842_ref2","doi-asserted-by":"publisher","DOI":"10.2307\/3349375"},{"key":"S2732494X25102842_ref18","doi-asserted-by":"publisher","DOI":"10.1086\/656623"},{"key":"S2732494X25102842_ref28","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10060745"},{"key":"S2732494X25102842_ref1","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2015105"},{"key":"S2732494X25102842_ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.8273"},{"key":"S2732494X25102842_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2023.05.008"},{"key":"S2732494X25102842_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2013.10.005"},{"key":"S2732494X25102842_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.10.006"},{"key":"S2732494X25102842_ref20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit498"},{"key":"S2732494X25102842_ref23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2147\/TCRM.S2838","article-title":"Impact upon clinical outcomes of translation of PNA FISH-generated laboratory data from the clinical microbiology bench to bedside in real time","volume":"4","author":"Ly","year":"2008","journal-title":"Therap Clin Risk Manag"},{"key":"S2732494X25102842_ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3973"},{"key":"S2732494X25102842_ref16","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00801-08"},{"key":"S2732494X25102842_ref22","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R439"},{"key":"S2732494X25102842_ref24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["Antimicrobial Stewardship &amp; Healthcare Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2732494X25102842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:00:51Z","timestamp":1775034051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2732494X25102842\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"alternative-id":["S2732494X25102842"],"URL":"https:\/\/doi.org\/10.1017\/ash.2025.10284","relation":{},"ISSN":["2732-494X"],"issn-type":[{"value":"2732-494X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e87"}}